Summary: Hebei Lansheng will invest more efforts in preparation for the 20,000 t/a clethodim TK project, which is planned to be located in its production base in Economic Development Zone of Jinzhou City, Hebei Province.

In late June 2022, CCM learned from Hebei Lansheng Biotech Co., Ltd. (Hebei Lansheng) that the company would invest more efforts in preparation for the 20,000 t/a 37% clethodim TK project. According to its plan, the new production line and supporting facilities will be situated in its existing clethodim workshops in the production base in Economic Development Zone of Jinzhou City, Hebei Province.

Hebei Lansheng, headquartered in Jinzhou City, has developed into a Top100 pesticide producer (by sales volume) as well as a leading player in clethodim industry in China. It has already put into operation a 4,000 t/a clethodim TC production line in the Jinzhou base. The 4,000 t/a capacity came after an expansion of 3,000 t/a passing completion acceptance in Jan. 2022, along with an expansion of boscalid TC capacity to 500 t/a from 50 t/a. In addition, its wholly-owned subsidiary, Hebei Lanrun Plant Protection Technology Co., Ltd. (Hebei Lanrun), also puts into operation the capacity of 1,000 t/a clethodim TC and 2,000 t/a clethodim TK. Obviously, Hebei Lansheng has steadily ramped up its investment in clethodim business.

Table Product and capacity of Hebei Lansheng and Hebei Lanrun

Echoing the latest development planning in its parent company, Hebei Lanrun has planned a pesticide TC & adjuvant production line transformation and environmental protection facilities upgrading project, to optimise its product mix and improve waste treatment. It proposes:

• Keep the capacity unchanged and conduct technological upgrading to the lines of 1,000 t/a clethodim TC, 2,000 t/a clethodim TK, 100 t/a sethoxydim TC, 300 t/a isoxadifen-ethyl, 500 t/a clethodim 120g/L EC and 900 t/a clethodim 240g/L EC;
• Keep the capacity unchanged and conduct technological upgrading to the line of 500 t/a spirotetramat TC, and repurpose old equipment to produce 2,5-dimethylphenylacetyl chloride, an intermediate of spirotetramat;
• Phase out the lines of 2,000 t/a metribuzin TC, 300 t/a haloxyfop-methyl TC, 200 t/a cyazofamid TC, 100 t/a picoxystrobin TC and 100 t/a flonicamid TC;
• Upgrade environmental protection facilities.

 

Originally, Hebei Lanrun wanted to expand spirotetramat TC capacity, but in the end it came to a final decision of maintaining the total capacity while upgrading production technology. From its proposed product plan, it is concluded that holding large-scale production capacity of clethodim products is still the focus of the company's development.